




# RESEARCH REPORT



## Cancer Immunotherapy Markets

*The Race for the Cures.*

Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides.

2023 to 2027



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Table of Contents

1 Market Guides .....18

1.1 Situation Analysis ..... 19

1.2 Guide for Executives and Marketing Staff ..... 21

1.3 Guide for Investment Analysts and Management Consultants..... 22

2 Introduction and Market Definition .....23

2.1 What is Cancer Immunotherapy? ..... 24

2.2 Immunotherapy – the looming cures ..... 25

2.3 Market Definition ..... 26

2.3.1 Market Size ..... 26

2.3.2 Currency ..... 26

2.3.3 Years ..... 26

2.4 Methodology..... 27

2.4.1 Methodology ..... 27

2.4.2 Sources ..... 27

2.4.3 Authors ..... 27

2.5 U.S. Medical Market and Pharmaceutical Spending - Perspective..... 29

2.5.1 Global Expenditures for Medicines ..... 29

3 Immunotherapy – Guide to Immune Technologies .....30

3.1 The Immune System ..... 31

3.1.1 Innate immune system..... 32

3.1.1.1 Surface barriers ..... 32

3.1.1.2 Inflammation ..... 33

3.1.1.3 Complement system ..... 34

3.1.1.4	Cellular barriers .....	34
3.1.1.5	Natural killer cells .....	36
3.1.2	Adaptive immune system .....	36
3.1.2.1	Lymphocytes.....	37
3.1.2.2	Killer T cells .....	37
3.1.2.3	Helper T cells .....	39
3.1.2.4	Gamma delta T cells .....	40
3.1.2.5	B lymphocytes and antibodies.....	40
3.1.3	Tumor immunology – the immune surveillance system.....	42
3.2	Immuno Oncology Technologies .....	44
3.2.1	Monoclonal Antibodies .....	44
3.2.1.1	Outlook for Monoclonal Antibodies.....	46
3.2.1.2	Companies with Monoclonal Antibodies in their Pipeline .....	47
3.2.2	Cancer vaccines.....	48
3.2.2.1	Outlook for Cancer Vaccines.....	49
3.2.2.2	Companies with Cancer Vaccines in their Pipeline .....	49
3.2.3	Cytokines.....	50
3.2.3.1	Outlook for Cytokines .....	50
3.2.3.2	Companies with Cytokines in their Pipeline.....	51
3.2.4	Cell Based Therapies.....	51
3.2.4.1	Outlook for Cell Based Therapies .....	53
3.2.4.2	Companies with Cell Based Therapies in their Pipeline .....	54
3.2.5	Inhibitors/Agonists.....	56
3.2.5.1	Outlook for Inhibitors/Agonists .....	56
3.2.5.2	Companies with Inhibitors/Agonists in their Pipeline.....	57
3.2.6	Antibody Drug Conjugates .....	58
3.2.6.1	Outlook for Antibody Drug Conjugates.....	60

3.2.6.2	Companies with Antibody Drug Conjugates in their Pipeline.....	60
3.2.7	Others .....	61
3.2.7.1	Outlook for Other Therapeutics .....	62
3.2.7.2	Companies with Viral Therapeutics in their Pipeline .....	62
3.2.7.3	Companies with Other Therapeutics in their Pipeline.....	62
4	Industry Overview.....	64
4.1	Market Players – Roles & Impacts .....	65
4.1.1	Drug manufacturers - Larger/pharmaceutical.....	65
4.1.2	Drug manufacturers - Generic .....	66
4.1.3	Contract Research and Manufacturing .....	67
4.1.4	In Vitro Diagnostics Industry .....	67
4.1.5	Drug Marketing Companies .....	68
4.1.6	Biotechnology Companies.....	68
4.1.7	Regulatory Bodies.....	69
5	Market Trends .....	70
5.1	Factors Driving Growth .....	71
5.1.1	Outcome potential .....	71
5.1.2	Fast tracking.....	72
5.1.3	Funding .....	72
5.1.4	Technology Environment .....	72
5.1.5	Target Solutions.....	73
5.2	Factors Limiting Growth .....	74
5.2.1	Cost of Treatment.....	74
5.2.2	Clinical Trials Role .....	75
5.2.3	Combinations .....	75
5.2.4	Protocols.....	75
5.3	Therapeutic Technology Development .....	76

5.3.1	Combinations - Issues and Complexity.....	76
5.3.2	Preference for a drug .....	77
5.3.3	Problems of Immunity Engineering.....	77
5.3.4	The Role of Cost.....	78
5.3.5	The Disruption Dynamic .....	78
5.3.6	CAR-T Cell Therapy.....	79
5.3.7	The Next Five Years.....	81
6	Cancer Immunotherapy Recent Developments .....	82
6.1	Recent Developments – Importance and How to Use This Section .....	83
6.1.1	Importance of These Developments .....	83
6.1.2	How to Use This Section.....	83
6.2	Continued Success with Immunotherapy in Melanoma .....	83
6.3	AC Immune Receives FDA Fast Track Designation .....	89
6.4	LTZ Announces Financing .....	90
6.5	Immunotherapy for Cancer Overview.....	91
6.6	Implantable device shrinks pancreatic tumors.....	94
6.7	mRNA Vaccine And Immunotherapy Reduce Melanoma Recurrence.....	96
6.8	Towards a Universal Cancer Immunotherapy .....	97
6.9	New Strategy May Improve T-Cell Therapy in Solid Tumors.....	99
6.10	Immunotherapy linked to increase in Medicare spending .....	101
6.11	Immunotherapy Effective with Ovarian Cancer .....	102
6.12	Cancer Immunotherapy Granted Fast Track .....	104
7	Profiles of Key Immunotherapy Companies .....	106
7.1	AbbVie .....	107
7.2	Achilles Therapeutics .....	109
7.3	Acumen Pharmaceuticals .....	110
7.4	Adagene .....	111

7.5	Adaptimmune Therapeutics .....	112
7.6	Adicet Bio .....	113
7.7	ALX Oncology Holdings .....	114
7.8	Ambrx Biopharma .....	115
7.9	Amgen .....	116
7.10	Apexigen .....	118
7.11	Arcus Biosciences.....	119
7.12	argenx.....	120
7.13	AstraZeneca .....	122
7.14	Atreca .....	124
7.15	Avalo Therapeutics .....	125
7.16	Avid Bioservices.....	126
7.17	Bavarian Nordic.....	127
7.18	BioAtla .....	128
7.19	Biogen Inc.....	129
7.20	BioNTech .....	131
7.21	Bolt Biotherapeutics .....	133
7.22	Bristol-Myers Squibb.....	134
7.23	Candel Therapeutics .....	136
7.24	Caribou Biosciences .....	137
7.25	Celldex Therapeutics .....	138
7.26	Checkpoint Therapeutics .....	139
7.27	Chinook Therapeutics .....	140
7.28	Corvus Pharmaceuticals .....	141
7.29	Cullinan Oncology .....	142
7.30	Eli Lilly .....	143
7.31	EOM Pharmaceuticals .....	145



7.32	Evaxion Biotech .....	146
7.33	Genenta Science .....	147
7.34	Gilead Sciences .....	148
7.35	Gracell Biotechnologies .....	149
7.36	Greenwich LifeSciences .....	150
7.37	Gritstone bio .....	151
7.38	Harpoon Therapeutics .....	152
7.39	ImmunityBio .....	153
7.40	Immunocore Holdings.....	154
7.41	Immunome .....	155
7.42	IMV Inc .....	156
7.43	Incyte .....	157
7.44	Indaptus Therapeutics .....	158
7.45	Instil Bio .....	159
7.46	lovance Biotherapeutics .....	160
7.47	Johnson & Johnson .....	161
7.48	Marker Therapeutics .....	163
7.49	Medicenna Therapeutics .....	164
7.50	Merck & Co.....	165
7.51	Merus.....	166
7.52	Moderna .....	167
7.53	Mustang Bio .....	168
7.54	Nanobiotix .....	170
7.55	Neoleukin Therapeutics .....	171
7.56	Novartis .....	172
7.57	Novavax.....	173
7.58	Oncorus.....	174

7.59	PDS Biotechnology .....	175
7.60	Pfizer .....	176
7.61	Regeneron Pharmaceuticals .....	177
7.62	Roche .....	179
7.63	Sanofi.....	180
7.64	Sensei Biotherapeutics .....	182
7.65	Senti Biosciences .....	183
7.66	Surface Oncology .....	184
7.67	Takeda Pharmaceutical.....	185
7.68	TC Biopharm .....	186
7.69	ThermoGenesis Holdings.....	187
7.70	UroGen Pharma .....	189
7.71	Werewolf Therapeutics .....	190
7.72	Xilio Therapeutics.....	191
7.73	Zymeworks .....	192
8	The Global Market for Immuno-Oncology Therapeutics .....	193
8.1	Global Market Overview by Country .....	194
8.1.1	Table – Global Market by Country.....	194
8.1.2	Chart - Global Market by Country .....	195
8.2	Global Market by Therapy - Overview .....	196
8.2.1	Table – Global Market by Therapy.....	196
8.2.2	Chart – Global Market by Therapy – Base/Final Year Comparison.....	197
8.2.3	Chart – Global Market by Therapy – Base Year.....	198
8.2.4	Chart – Global Market by Therapy – End Year .....	199
8.2.5	Chart – Global Market by Therapy – Share by Year.....	200
8.2.6	Chart – Global Market by Therapy – Segments Growth .....	201
8.3	Global Market by Cancer - Overview.....	202

8.3.1	Table – Global Market by Cancer .....	202
8.3.2	Chart – Global Market by Cancer – Base/Final Year Comparison .....	203
8.3.3	Chart – Global Market by Cancer – Base Year .....	204
8.3.4	Chart – Global Market by Cancer – End Year .....	205
8.3.5	Chart – Global Market by Cancer – Share by Year .....	206
8.3.6	Chart – Global Market by Cancer – Segments Growth.....	207
8.4	Global Market by Customer - Overview .....	208
8.4.1	Table – Global Market by Customer.....	208
8.4.2	Chart – Global Market by Customer – Base/Final Year Comparison.....	209
8.4.3	Chart – Global Market by Customer – Base Year.....	210
8.4.4	Chart – Global Market by Customer – End Year .....	211
8.4.5	Chart – Global Market by Customer – Share by Year .....	212
8.4.6	Chart – Global Market by Customer – Segments Growth .....	213
9	Global Immuno-Oncology Therapy Markets – By Therapy .....	214
9.1	MAB.....	215
9.1.1	Table MAB – by Country .....	215
9.1.2	Chart - MAB Growth.....	216
9.2	Cytokine.....	217
9.2.1	Table Cytokine – by Country .....	217
9.2.2	Chart - Cytokine Growth .....	218
9.3	Vaccine .....	219
9.3.1	Table Vaccine – by Country.....	219
9.3.2	Chart - Vaccine Growth.....	220
9.4	Cell Based.....	221
9.4.1	Table Cell Based – by Country .....	221
9.4.2	Chart – Cell Based Growth .....	222
9.5	Inhibitor/Agonist .....	223

9.5.1	Table Inhibitor/Agonist – by Country.....	223
9.5.2	Chart – Inhibitor/Agonist Growth .....	224
9.6	Other IO Therapy.....	225
9.6.1	Table Other IO Therapy – by Country .....	225
9.6.2	Chart – Other IO Therapy Growth.....	226
10	Global Immuno-Oncology Therapeutic Markets – By Cancer.....	227
10.1	Breast.....	228
10.1.1	Table Breast – by Country .....	228
10.1.2	Chart - Breast Growth .....	229
10.2	ColoRectal.....	230
10.2.1	Table ColoRectal – by Country .....	230
10.2.2	Chart - ColoRectal Growth .....	231
10.3	Cervical.....	232
10.3.1	Table Cervical – by Country .....	232
10.3.2	Chart - Cervical Growth .....	233
10.4	Lung.....	234
10.4.1	Table Lung – by Country .....	234
10.4.2	Chart - Lung Growth .....	235
10.5	Precancer .....	236
10.5.1	Table Precancer – by Country .....	236
10.5.2	Chart - Precancer Growth.....	237
10.6	Prostate .....	238
10.6.1	Table Prostate – by Country .....	238
10.6.2	Chart – Prostate Growth .....	239
10.7	Melanoma .....	240
10.7.1	Table Melanoma – by Country .....	240
10.7.2	Chart - Melanoma Growth.....	241

10.8	Blood .....	242
10.8.1	Table Blood – by Country .....	242
10.8.2	Chart - Blood Growth.....	243
10.9	Other Cancer .....	244
10.9.1	Table Other Cancer – by Country .....	244
10.9.2	Chart – Other Cancer Growth .....	245
11	Global Immuno-Oncology Therapeutic Markets – By Customer .....	246
11.1	Pharma.....	247
11.1.1	Table Pharma – by Country.....	247
11.1.2	Chart - Pharma Growth .....	248
11.2	Clinic.....	249
11.2.1	Table Clinic – by Country.....	249
11.2.2	Chart - Clinic Growth .....	250
11.3	Other Customer.....	251
11.3.1	Table Other Customer – by Country .....	251
11.3.2	Chart - Other Customer Growth .....	251
12	Appendices.....	252
12.1	FDA Cancer Drug Approvals by Year.....	253
12.2	Clinical Trials Started .....	254
12.3	Prevalence of Cancer Treatments .....	255

## Table of Tables

Table 1 List of Cancers by Mortality .....	25
Table 2 Overview of Innate and Adaptive Immunity .....	32
Table 3 Approval Rates of Therapeutic Antibodies .....	44
Table 4 Monoclonal Antibody Companies .....	47
Table 5 Cancer Vaccine Companies.....	49
Table 6 Cytokine Companies .....	51
Table 7 Cell Based Therapy Companies.....	54
Table 8 Inhibitor/Agonist Companies.....	57
Table 9 Antibody Drug Conjugate Companies .....	61
Table 10 Viral Therapeutics Companies .....	62
Table 11 Other Therapeutics Companies .....	62
Table 12 Market Players by Type .....	65
Table 13 Five Factors Driving Growth .....	71
Table 14 Four Factors Limiting Growth .....	74
Table 15 - Global Market by Region .....	194
Table 16 Global Market by Therapy.....	196
Table 17 Global Market by Cancer .....	202
Table 18 Global Market by Customer.....	208
Table 19 MAB by Country .....	215
Table 20 Cytokine by Country .....	217
Table 21 Vaccine by Country.....	219
Table 22 Cell Based by Country .....	221
Table 23 Inhibitor/Agonist by Country.....	223
Table 24 Other IO Therapy by Country .....	225

Table 25 Breast by Country .....	228
Table 26 ColoRectal by Country .....	230
Table 27 Cervical by Country .....	232
Table 28 Lung by Country .....	234
Table 29 Precancer by Country .....	236
Table 30 Prostate by Country .....	238
Table 31 Melanoma by Country.....	240
Table 32 Blood by Country.....	242
Table 33 Other Cancer by Country.....	244
Table 34 Pharma by Country .....	247
Table 35 Clinic by Country .....	249
Table 36 Other Customer by Country .....	251

## Table of Figures

Figure 1 Medicine Expenditures Perspective.....	29
Figure 2 Helper T Cell Roles .....	39
Figure 3 Antibody Diagram.....	41
Figure 4 Macrophages attack a Cancer Cell.....	42
Figure 5 CAR-T Clinical Trials.....	53
Figure 6 Antibody Drug Conjugate Diagram .....	59
Figure 7 Growth rates of IO Therapies.....	81
Figure 8 Global Market Pareto Chart.....	195
Figure 9 Global Market by Therapy - Base vs. Final.....	197
Figure 10 Global Market by Therapy Base Year .....	198
Figure 11 Global Market by Therapy End Year .....	199
Figure 12 Therapy Share by Year.....	200
Figure 13 Therapy Segments Growth .....	201
Figure 14 Global Market by Cancer - Base vs. Final .....	203
Figure 15 Global Market by Cancer Base Year .....	204
Figure 16 Global Market by Cancer End Year .....	205
Figure 17 Cancer Share by Year .....	206
Figure 18 Cancer Segments Growth.....	207
Figure 19 Global Market by Customer - Base vs. Final.....	209
Figure 20 Global Market by Customer Base Year .....	210
Figure 21 Global Market by Customer End Year.....	211
Figure 22 Customer Share by Year .....	212
Figure 23 Customer Segments Growth .....	213
Figure 24 MAB Growth.....	216



Figure 25 Cytokine Growth .....	218
Figure 26 Vaccine Growth .....	220
Figure 27 Cell Based Growth .....	222
Figure 28 Inhibitor/Agonist Growth.....	224
Figure 29 Other IO Therapy Growth .....	226
Figure 30 Breast Growth .....	229
Figure 31 ColoRectal Growth .....	231
Figure 32 Cervical Growth .....	233
Figure 33 Lung Growth .....	235
Figure 34 Precancer Growth.....	237
Figure 35 Prostate Growth.....	239
Figure 36 Melanoma Growth.....	241
Figure 37 Blood Growth.....	243
Figure 38 Other Cancer Growth.....	245
Figure 39 Pharma Growth .....	248
Figure 40 Clinic Growth .....	250
Figure 41 Other Customer Growth .....	251
Figure 42 FDA Cancer Drug Approvals by Year.....	253
Figure 43 Clinical Trials for Immunotherapy by Year .....	254
Figure 44 Pie Chart of Prevalence of Cancer Treatments .....	255